Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs

Pharmacotherapy

Volumn 19, Issue 4 I, 1999, Pages 437-441

  Chen, Chao ^a   Casale, Eugene J ^a   Duncan, Benjamin ^a   Culverhouse, Elizabeth H ^a   Gilman, Jamie ^b  

^a GLAXOSMITHKLINE   (United States)

^b MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ARTICLE; CHILD; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EPILEPSY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION;

EID: 0032903194     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.6.437.31052     Document Type: Article

References (34)

1. Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. II. Neurochemical studies on the mechanism of action. Epilepsia 1986;27:490-7.
2. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
3. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35(1):113-21.
4. Schachter SC, Leppik IE, Matsuo F, et al. Lamotrigine: a six-month, placebo-controlled, safety and tolerance study. J Epilepsy 1995;8:201-9.
5. Loiseau P, Yuen AWC, Duche B, Menager T, Arne-Bes MC. A randomized double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45.
6. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial seizures. Epilepsia 1993;34(2):312-22.
7. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment of resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56:448-53.
8. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30(3):356-63.
9. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345(8948):476-9.
10. Steiner TJ, Yuen AWC. Comparison of lamotrigine (Lamictal) and phenytoin monotherapy in newly diagnosed epilepsy [abstr]. Epilepsia 1994;35(suppl 7):61.
11. Reunanen M, Dam M, Yuen AWC. A randomized open multicenter comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-55.
12. Chang G, Vazquez B, Gilliam F, et al. Lamictal (lamotrigine) monotherapy is an effective treatment for partial seizures. Neurology 1997;48(3):A335.
13. Chang G, Vazquez B, Gilliam F, et al. Lamictal (lamotrigine) monotherapy is a safe and effective treatment for partial seizures. Epilepsia 1997;38(suppl 3):32.
14. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46(1):1-25.
15. Annegers JF. Epidemiology of childhood onset seizures. In: Dodson WE, Pellock JM, eds. Pediatric epilepsy: diagnosis and therapy. New York: Demos Publications, 1993:57-61.
16. Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994;35(suppl 2):S1-6.
17. Tharp B. An overview of pediatric seizure disorders and epileptic syndromes. Epilepsia 1987;28(suppl 1):S36-45.
18. Hauser WA, Hesdorffer DH. Epilepsy: frequency, causes and consequences. New York: Demos Publications, 1990.
19. Leviton A, Cowan LD. Epidemiology of seizure disorders in children. Neuroepidermiology 1982;1:40-83.
20. Mullens L, Gallagher J, Manasco P. Improved neurological function accompanies effective control of the Lennox-Gastaut syndrome with Lamictal: results of a multinational, placebo-controlled trial. Epilepsia 1996;37(suppl 5):163.
21. Trevathan E, Motte J, Arvidsson J, Manasco P, Mullens L. Safety and tolerability of adjunctive Lamictal for the treatment of the Lennox-Gastaut syndrome: results of a multinational, double-blind, placebo-controlled trial. Epilepsia 1996;37(suppl 5):202.
22. Frank LM, Casale EJ, Womble G, Manasco P. Lamictal is effective for the treatment of typical absence seizures in children and adolescents. Ann Neurol 1997;42:489.
23. Besag FM, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127(6):991-7.
24. Wallace SJ. Add-on open trial of lamotrigine in resistant childhood seizures. Brain Dev 1990;12(5):734.
25. Vauzelle-Kervroedan F, Rey E, Cieuta C, et al. Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. Br J Clin Pharmacol 1996;41:325-30.
26. Eriksson AS, Hoppu K, Nergardh A, Boreus L. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996;37(8):769-73.
27. Rowe PC. The Harriet Lane handbook. Chicago: Year Book Medical Publishers, 1987.
28. Sailstad JM, Findlay JWA. Immunofluorometric assay for lamotrigine (Lamictal) in human plasma. Ther Drug Monit 1991;13:433-42.
29. Scientific Consulting, Inc. WINNONLIN user's guide. Cary, NC: Author, 1995.
30. Perucca E. Drug metabolism in pregnancy, infancy and childhood. Pharmacol Ther 1987;34:129-43.
31. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996;60:145-56.
32. Glaxo Wellcome Inc. Lamictal (lamotrigine) package insert. Research Triangle Park, NC;1998.
33. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
34. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43:457-65.